Experimental bovine pneumonic pasteurellosis. II. Genesis and prevention.
Two experiments were conducted. In the first, 16 crossbred Hereford calves were divided into two equal groups. The first group was vaccinated intranasally with a commercial vaccine against bovid herpesvirus 1 and the second group was unvaccinated. The calves were later exposed to an aerosol of bovid herpesvirus 1 (strain 108) for five minutes. Four calves from each group were subjected to transportation and four calves from each group were kept in an environmental chamber for four days. Four days after viral aerosol all calves were exposed to an aerosol of Pasteurella haemolytica and the same subgroups were again transported or held in the chamber for a further four days. The calves that did not die from pneumonia were necropsied ten days after the final day of transport. Pulmonary lesions were present in both vaccinated and control animals but were less extensive in the vaccinated calves. Six of eight vaccinated but none of the eight control calves survived. In the second experiment, eight crossbred Hereford calves were divided into two equal groups. One group was vaccinated with bovid herpesvirus 1 (strain 108) and the other acted as controls. Four weeks later all calves were sequentially exposed to aerosols of bovid herpesvirus 1 (strain 108) and P. haemolytica four days apart. Three of the four controls but none of the vaccinates died from pneumonia. Every lobe of the lungs in all the controls was affected by pneumonia while no pulmonary lesions were found in the vaccinated calves. The differences in efficacy of the modes of vaccination and the possible role of transport stress are discussed.
D000818:Animals; D002417:Cattle; D002418:Cattle Diseases / Q000209:etiology* / Q000517:prevention & control; D006564:Herpesviridae / Q000276:immunology; D010326:Pasteurella Infections / Q000209:etiology / Q000517:prevention & control / Q000662:veterinary*; D011014:Pneumonia / Q000209:etiology / Q000517:prevention & control / Q000662:veterinary*; D014765:Viral Vaccines / Q000627:therapeutic use
D014765:Viral Vaccines